---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-119795"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T07:10:37.158925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pediatrix Q3 adjusted EPS $0.44, revenue $511M; reaffirms FY 2024 EBITDA guidance $205-215M

## Summary
- Net revenue $511M, up from $506.6M YoY; same-unit revenue grew 5.2% (reimbursement +3.4%, volume +1.8%).
- GAAP EPS $0.23, down from $0.26 YoY; Adjusted EPS $0.44 vs $0.32; Adjusted EBITDA $60M vs $50.4M.
- Exiting almost all office-based practices (except maternal-fetal medicine); expects ~$30M annualized EBITDA benefit by year-end.
- Cash from operations $95.7M; total debt $619M, no revolver borrowings; completed hybrid RCM transition.
- FY 2024 Adjusted EBITDA guidance $205-215M, implying Q4 roughly $50-60M based on YTD result of $155.3M.

## SEC filing metadata
- accession: 0000950170-24-119795
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000095017024119795/0000950170-24-119795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000095017024119795/md-20241101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-119795
- JSON: https://secwatch.observer/filing/0000950170-24-119795.json
- Plain text: https://secwatch.observer/filing/0000950170-24-119795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.